Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma

NCT06468605 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Immorna, the funder withdrew the funds to run this study

Conditions

Recurrent or Progressive High-grade Glioma

Interventions

BIOLOGICAL: JCXH-211

Sponsor

Duke University